The stock of ADMA Biologics Inc. (NASDAQ:ADMA) decreased by -$0.01 on Tuesday to finish at $3.78, down -0.26 percent. The last five days have seen an average of 2,149,960 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$0.10. The average number of shares traded over the last 20 days was 2,937,560, while the average volume over the last 50 days totaled 2,160,808.
ADMA stock dropped -8.92% since last month. On 08/29/23, the company’s shares reached a one-month low of $3.75. The stock touched a high of $4.65 on 08/15/23, after rallying from a low of $2.24 in 52 weeks. The price of ADMA stock has declined by -2.58% or -$0.10 this year, reaching a new high 6 times. Still, the stock price is down -18.71% from the 52-week high.
Insider Transactions
ADMA stock investors should be aware that ADMA Biologics Inc. (ADMA) stock had its last reported insider trading activity 6 days ago on Aug 24. On Aug 24, Director KWON YOUNG acquired 25,000 shares at $3.90 each. This transaction resulted in the insider spending $97,500. On Aug 22, Fong Bryant sold 1,433,304 shares at a price of US$3.87. After the transaction, the insider now owns 0 shares. President and CEO Grossman Adam S had earlier sold 250,000 shares on Aug 18 for $4.15 a share. The transaction was completed for $1,038,350.
Valuation Metrics
Beta for the stock is 0.81. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.00, the price-to-book (PB) ratio of 5.73.
Financial Health
For the three months ended June 29, ADMA Biologics Inc.’s quick ratio was 2.50, while its current ratio was 6.30, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.96, and the total debt to equity ratio is 0.96. As far as profitability goes, gross margin for the trailing twelve months is 27.40% percent. ADMA Biologics Inc.’s EBITDA margin for the year ended June 29 was -21.07%, whereas its operating margin stood at -8.00% for the same period. Based on annual data, it had gross profit of $35.27 million and revenue of $154.08 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ADMA’s return on assets (ROA) during the last 12 months has been -12.10%. There was a -15.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -29.60%.
Earnings Surprise
According to ADMA Biologics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $59.69 million, while revenues rose by 43.19% to $56.91 million. It was predicted that ADMA Biologics Inc.’s quarterly earnings would be -$0.03, but it ended up being -$0.02. EBITDA was $2.28 million for the quarter. At the end of ADMA Biologics Inc.’s most recent quarter ended June 29, its liabilities totaled 196.26 million, while its total debt was $151.51 million. Equity owned by shareholders amounts to $224.91 million.
Technical Picture
Here’s a quick look at ADMA Biologics Inc.’s (ADMA) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 35.94%, suggesting the stock is Neutral, with a 40.90% historical volatility rate.
The stochastic %K and %D were 7.24% and 10.41% respectively, while the average true range (ATR) was 0.18. Based on the 14-day stochastic reading of 3.33%, the RSI (14) reading is 41.18%. On the 9-day MACD Oscillator, the stock is at -0.13, and the 14-day reading is at -0.31.
Analyst Ratings
Analysts have assigned ADMA Biologics Inc. (ADMA) an Buy rating. ADMA is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is ADMA’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $7.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for ADMA Biologics Inc. (ADMA) is $6.00.
